Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer

• Published in: Scientific reports 2023-11, Vol.13 (1), p.19399-19399, Article 19399
• Main Authors: Fukahori, Masaru, Okabe, Yoshinobu, Shimokawa, Mototsugu, Otsuka, Taiga, Koga, Futa, Ueda, Yujiro, Nakazawa, Junichi, Komori, Azusa, Otsu, Satoshi, Arima, Shiho, Makiyama, Akitaka, Taguchi, Hiroki, Honda, Takuya, Ushijima, Tomoyuki, Miwa, Keisuke, Shibuki, Taro, Nio, Kenta, Ide, Yasushi, Ureshino, Norio, Mizuta, Toshihiko, Mitsugi, Kenji, Shirakawa, Tsuyoshi
• Format: Article
• Language: English
• Subjects: 631/67; 692/308; 692/4020; 692/4028; Chemotherapy; Gemcitabine; Humanities and Social Sciences; Metastases; Metastasis; multidisciplinary; Paclitaxel; Pancreatic cancer; Patients; Science; Science (multidisciplinary); Survival
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-46924-0

First-line chemotherapy for patients with metastatic pancreatic cancer (MPC) includes gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX (FFX). However, the efficacy of second-line chemotherapy and the role of combination chemotherapy in clinical practice is still unknown. Data was gathered from 14 hospitals in the Kyushu area of Japan from December 2013 to March 2017. The median overall survival (mOS) from second-line treatment was contrasted between patients who received second-line chemotherapy (CT group) and those who received the best supportive care (BSC group). Furthermore, the mOS of combination chemotherapy was compared to mono chemotherapy in the CT group. To control possible bias in the selection of treatment, we performed a propensity score-adjusted analysis. A total of 255 patients received GnP or FFX as first-line chemotherapy. There were 156 in the CT group and 77 in the BSC group of these. The CT group had a significantly longer mOS than the BSC group (5.2 vs. 2.6 months; adjusted hazard ratio (HR) 0.38; 95% CI 0.27–0.54). In the CT group, 89 patients received combination chemotherapy while 67 received mono chemotherapy. The mOS did not differ significantly between the combination and mono chemotherapy groups (5.5 vs. 4.8 months; adjusted HR 0.88; 95% CI 0.58–1.33). Among patients with MPC receiving second-line treatment, the CT group had a significantly longer mOS than the BSC group, but combination chemotherapy conferred no improvement in survival compared to mono chemotherapy.